RESORB Clinical Trial for Knee Osteoarthritis Pain
Vascular and Embolization Specialists Highlights Participation in a Pivotal Genicular Artery Embolization Study
COCOA, FL, May 20, 2026 — Vascular and Embolization Specialists, an outpatient vascular and embolization practice in Cocoa, Florida, is highlighting its involvement in the RESORB clinical trial, a pivotal randomized study evaluating genicular artery embolization for osteoarthritic knee pain. The study compares genicular artery embolization using Nexsphere F™ with intra articular corticosteroid knee injection in adults with knee osteoarthritis pain.
RESORB is listed on ClinicalTrials.gov as Randomized Controlled Study Evaluating Genicular Artery Embolization Against Intra Articular Corticosteroid Knee Injection for Osteoarthritic Knee Pain under identifier NCT06872567. The study record describes RESORB as a recruiting, interventional, randomized, open label trial with an estimated enrollment of 126 participants. The trial evaluates genicular artery embolization and corticosteroid injection, with primary outcome measures including changes in the Western Ontario and McMaster Universities Osteoarthritis Index and serious adverse events across follow up intervals.
Vascular and Embolization Specialists lists RESORB among its active clinical trials and describes the study as a pivotal trial enrolling about 126 patients across more than 10 leading United States clinical sites. The clinic’s RESORB information states that the trial compares genicular artery embolization with Nexsphere F™ to intra articular corticosteroid injections for painful knee osteoarthritis, assessing safety and efficacy.
About the RESORB Clinical Trial
The trial focuses on genicular artery embolization, a minimally invasive, image guided procedure designed to target abnormal blood flow associated with knee inflammation. Vascular and Embolization Specialists describes GAE as a nonsurgical procedure for osteoarthritis knee pain that uses catheter based X ray guidance to deliver tiny particles into vessels feeding inflamed knee tissues, with the goal of reducing blood flow and inflammation.
Nexsphere F™ is an investigational resorbable microsphere technology developed by NEXTBIOMEDICAL CO., LTD. NEXTBIOMEDICAL announced FDA Investigational Device Exemption approval for Nexsphere F™ and the RESORB trial in January 2025, describing RESORB as a multicenter, randomized, open label study designed to assess Nexsphere F™ in alleviating pain and improving mobility in patients with knee osteoarthritis. The company later announced that Nexsphere F™ received FDA Breakthrough Device Designation on March 6, 2025 for musculoskeletal pain embolization, with a proposed indication involving temporary occlusion of blood flow in the genicular arteries for knee osteoarthritis pain in patients who have not responded adequately to conservative treatment or analgesics.
Endovascular Today reported that RESORB would enroll approximately 126 patients at more than 10 centers in the United States, and that Nexsphere F™ is designed to temporarily occlude pathologic microvasculature supplying pain generating tissues before dissolving within 2 to 6 hours. According to client provided enrollment information, the Joint Vascular group is contributing 95 percent of enrolled patients, a participation level that should be internally confirmed immediately before publication because enrollment figures may change during an active clinical trial.
Clinical Research Behind Nexsphere F™
The trial builds on a growing body of research into temporary embolic agents for musculoskeletal pain. A 2025 Journal of Vascular and Interventional Radiology study listed by PubMed evaluated three rapidly biodegraded embolic materials in transcatheter arterial embolization for degenerative, inflammatory, and overuse joint disorders. In that study, resorbable microspheres were used in 155 patients, and the abstract reported no severe adverse events and improvement in mean numeric rating scale pain scores from 7.0 at baseline to 2.3 at 6 months for the resorbable microsphere group. Endovascular Today summarized those 155 patient results as a 67 percent mean reduction in pain at 6 months with no device related serious adverse events.
Additional peer reviewed evidence continues to evaluate the safety and clinical outcomes of genicular artery embolization using resorbable gelatin microspheres. A 2025 Cardiovascular and Interventional Radiology article available through PubMed Central evaluated GAE using resorbable gelatin microspheres in 45 patients with knee osteoarthritis or persistent pain after total knee replacement, reporting short term clinical improvement and no major complications.
For patients and referring providers on Florida’s Space Coast, Vascular and Embolization Specialists’ involvement in RESORB reinforces the practice’s role in bringing clinical research opportunities to the outpatient interventional setting. The practice is located at 2300 FL 524, Suite 106, Cocoa, FL 32926, and provides minimally invasive vascular and embolization services for patients in Cocoa and surrounding Space Coast communities.
About Vascular and Embolization Specialists
Vascular and Embolization Specialists is an outpatient vascular and embolization practice in Cocoa, Florida. Led by Dr. Derek Mittleider, M.D., FSIR, the practice focuses on minimally invasive, image guided treatments for vascular conditions and embolization based procedures, including genicular artery embolization for osteoarthritis knee pain.
About RESORB
RESORB is a randomized clinical study evaluating genicular artery embolization with Nexsphere F™ against intra articular corticosteroid knee injection for osteoarthritic knee pain. ClinicalTrials.gov lists the study as NCT06872567, with an estimated enrollment of 126 participants and a recruiting status as of the latest public record reviewed.
Important Research Notice
Nexsphere F™ is listed on ClinicalTrials.gov as an unapproved or uncleared FDA regulated device product for this study. In the United States, Vascular and Embolization Specialists states that Nexsphere F™ is available only through the RESORB clinical trial. Participation in a clinical trial is subject to eligibility criteria, informed consent, trial site availability, and investigator review. Individual results are not guaranteed and may vary.
